Top Page
GlaxoSmithKline
(LSE:GSK)
GlaxoSmithKline (GSK) vs. S&P 500 (SPY)
GlaxoSmithKline Business Overview & Revenue Model
GlaxoSmithKline Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 31.38B | 30.33B | 29.32B | 34.11B | 34.10B | Gross Profit |
| 22.33B | 21.76B | 19.77B | 22.51B | 22.39B | EBIT |
| 4.02B | 6.75B | 6.43B | 6.20B | 7.78B | EBITDA |
| 6.67B | 9.14B | 8.63B | 7.76B | 10.16B | Net Income Common Stockholders |
| 2.58B | 4.93B | 4.92B | 4.38B | 5.75B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 3.71B | 5.69B | 7.88B | 4.33B | 6.37B | Total Assets |
| 59.46B | 59.01B | 60.15B | 79.10B | 80.43B | Total Debt |
| 16.99B | 18.02B | 20.99B | 24.17B | 27.15B | Net Debt |
| 13.29B | 15.08B | 17.26B | 19.90B | 20.86B | Total Liabilities |
| 46.38B | 46.21B | 50.05B | 57.76B | 59.62B | Stockholders Equity |
| 13.67B | 13.35B | 10.60B | 15.05B | 14.59B |
| Cash Flow | Free Cash Flow | |||
| 3.57B | 4.42B | 5.14B | 5.02B | 6.20B | Operating Cash Flow |
| 6.55B | 6.77B | 7.40B | 7.95B | 8.44B | Investing Cash Flow |
| -1.23B | -1.59B | -8.77B | -1.78B | 2.16B | Financing Cash Flow |
| -4.73B | -5.64B | 823.00M | -7.59B | -10.13B |
GlaxoSmithKline Technical Analysis
GlaxoSmithKline Risk Analysis
GlaxoSmithKline Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | £166.76B | 27.27 | 19.90% | 2.28% | 13.74% | 21.45% | |
72 Outperform | £4.42B | 15.80 | 15.79% | 3.08% | 5.83% | 83.35% | |
71 Outperform | £58.60B | 18.76 | 22.52% | 4.21% | 2.57% | -30.13% | |
54 Neutral | £867.13M | ― | ― | 5.76% | -729.39% | ||
52 Neutral | $5.35B | 3.96 | -42.60% | 2.86% | 17.58% | 1.27% |
GlaxoSmithKline Earnings Call Summary
GlaxoSmithKline Corporate Events
GSK has announced the purchase of 709,955 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategic financial management and aims to enhance shareholder value by holding these shares in treasury. The buyback program underscores GSK’s commitment to optimizing its capital structure and potentially improving its earnings per share, thereby strengthening its position in the healthcare industry.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline demonstrates stable financial performance with strong earnings guidance and strategic initiatives enhancing shareholder value. Notable strengths include its robust dividend yield and specialty medicines growth, though technical indicators suggest caution due to trading below key moving averages. Challenges in managing leverage and legal risks remain, but the overall outlook is positive, supported by recent product approvals and strategic buybacks.
To see Spark’s full report on GB:GSK stock, click here.
GSK plc has announced its total voting rights and capital structure as of April 30, 2025, in accordance with the Financial Conduct Authority’s rules. The company’s issued share capital consists of over 4.3 billion ordinary shares, with a total of 4.1 billion voting rights available to shareholders. This update is crucial for shareholders to calculate their interests and comply with regulatory requirements.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline demonstrates stable financial performance with strong earnings guidance and strategic initiatives enhancing shareholder value. Notable strengths include its robust dividend yield and specialty medicines growth, though technical indicators suggest caution due to trading below key moving averages. Challenges in managing leverage and legal risks remain, but the overall outlook is positive, supported by recent product approvals and strategic buybacks.
To see Spark’s full report on GB:GSK stock, click here.
GSK announced positive results from the MATINEE phase III trial for Nucala (mepolizumab) in treating chronic obstructive pulmonary disease (COPD). The trial demonstrated significant reductions in COPD exacerbations, including a 21% reduction in moderate/severe exacerbations and a 35% reduction in exacerbations leading to emergency visits or hospitalizations. These findings highlight Nucala’s potential to improve patient outcomes and address a major healthcare challenge, as COPD-related hospitalizations are projected to become a leading cause of medical admissions.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s stock is supported by a stable financial performance and strategic initiatives like share buybacks and product approvals. While technical indicators suggest caution, the company’s strong earnings guidance and specialty medicines growth provide a positive outlook. Challenges include managing leverage and legal costs.
To see Spark’s full report on GB:GSK stock, click here.
GSK has announced the purchase of 685,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, is part of a non-discretionary agreement and reflects GSK’s strategy to manage its capital structure and enhance shareholder value. Following this purchase, GSK holds over 204 million shares in treasury, with a total of over 4.1 billion shares in issue, excluding treasury shares. This move is likely to impact the company’s stock liquidity and could influence shareholder decisions regarding their interests in the company.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s stock is supported by stable financials and strategic initiatives like share buybacks. Despite technical caution and challenges in leverage management and legal costs, strong earnings guidance and specialty medicines growth provide a positive outlook.
To see Spark’s full report on GB:GSK stock, click here.
GSK reported a strong start to 2025 with significant growth in sales, profits, and earnings, driven by its Specialty Medicines segment. The company achieved a 4% increase in total Q1 sales to £7.5 billion, with notable contributions from oncology and respiratory medicines. GSK also highlighted its pipeline progress, expecting five major FDA product approvals in 2025, and emphasized its commitment to shareholder returns with a declared dividend and a share buyback program. The company remains confident in its 2025 guidance, projecting turnover growth of 3% to 5% and core operating profit growth of 6% to 8%, supported by strategic investments in R&D and operational efficiencies.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s stock is supported by stable financials and strategic initiatives like share buybacks. Despite technical caution and challenges in leverage management and legal costs, strong earnings guidance and specialty medicines growth provide a positive outlook.
To see Spark’s full report on GB:GSK stock, click here.
GSK has announced the purchase of 688,703 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move, which is in line with a non-discretionary agreement established earlier in the year, is aimed at consolidating the company’s shareholding structure, potentially enhancing shareholder value and reflecting confidence in its financial stability.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.
GlaxoSmithKline’s stock score reflects a stable financial performance with strengths in specialty medicines and shareholder returns. While the valuation and dividend yield are positive, technical indicators suggest caution. Continued focus on improving leverage management and addressing legal risks will be crucial. Strategic initiatives, such as share buybacks and new product approvals, bolster the company’s future growth prospects.
To see Spark’s full report on GB:GSK stock, click here.
GSK has announced the purchase of 824,200 of its own ordinary shares as part of its ongoing share buyback program, facilitated by Citigroup Global Markets Limited. This move is part of a non-discretionary agreement aimed at optimizing the company’s capital structure, potentially enhancing shareholder value and reflecting confidence in the company’s financial health.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.
GlaxoSmithKline’s overall stock score reflects a robust financial position with strong cash flow and strategic initiatives like share buybacks and product approvals. Despite some technical caution due to trading below key moving averages, the company benefits from fair valuation and positive earnings guidance. Key strengths in specialty medicines and shareholder returns bolster the outlook, although challenges in leverage management and legal costs present ongoing risks.
To see Spark’s full report on GB:GSK stock, click here.
GSK has announced the purchase of 715,130 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, is part of a non-discretionary agreement and reflects GSK’s strategy to manage its capital structure effectively. The shares will be held as treasury shares, contributing to the company’s financial flexibility and potentially enhancing shareholder value.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s stock score reflects a robust financial position with strong cash flow and strategic initiatives like share buybacks and product approvals. Despite some technical caution due to trading below key moving averages, the company benefits from fair valuation and positive earnings guidance. Key strengths in specialty medicines and shareholder returns bolster the outlook, although challenges in leverage management and legal costs present ongoing risks.
To see Spark’s full report on GB:GSK stock, click here.
GSK has announced the repurchase of 711,400 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move, which is part of a non-discretionary agreement, aims to manage the company’s capital structure and return value to shareholders, potentially enhancing shareholder confidence and stabilizing share prices.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.
GlaxoSmithKline demonstrates a stable financial performance with notable strengths in specialty medicines and shareholder return strategies. The fair valuation and strong dividend yield support its investment appeal. However, technical indicators suggest caution, and challenges include managing leverage and legal costs. Positive earnings guidance and strategic corporate events bolster the stock’s outlook.
To see Spark’s full report on GB:GSK stock, click here.
GSK plc announced the purchase of 684,200 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategic financial management and commitment to enhancing shareholder value. The shares will be held as treasury shares, and the total number of voting rights in the company remains unchanged at 4,115,579,330. This move is part of a broader strategy to optimize capital allocation and improve earnings per share, potentially impacting investor confidence and market perception positively.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GSK’s overall stock score reflects strong financial performance and strategic corporate actions, such as product approvals and share buybacks. Despite positive earnings guidance and a robust dividend yield, technical indicators suggest caution. Managing leverage and legal costs remain key challenges.
To see Spark’s full report on GB:GSK stock, click here.
GSK has announced the UK MHRA’s approval of Blenrep combinations for treating relapsed/refractory multiple myeloma, marking the first global authorization in this setting. The approval is based on superior efficacy results from the DREAMM-7 and DREAMM-8 phase III trials, which demonstrated significant improvements in progression-free and overall survival compared to standard treatments. This development positions Blenrep as a potentially transformative therapy in the treatment landscape, offering a differentiated mechanism of action and addressing the urgent need for more effective multiple myeloma treatments.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score reflects a stable financial performance with notable strengths in specialty medicines growth and shareholder return strategies. The company’s fair valuation and strong dividend yield support its attractiveness as an investment. However, technical indicators suggest caution, and challenges such as managing leverage and legal costs present risks. The positive earnings call and strategic corporate events further bolster the outlook.
To see Spark’s full report on GB:GSK stock, click here.
GSK plc has announced an increase in notional interest in its ordinary shares for several of its senior executives, including the CEO and CFO, following the reinvestment of dividends paid to shareholders. This transaction, conducted on the London Stock Exchange, reflects the company’s ongoing commitment to aligning executive interests with shareholder value, potentially impacting its market positioning and stakeholder confidence.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score reflects a stable financial performance with notable strengths in specialty medicines growth and shareholder return strategies. The company’s fair valuation and strong dividend yield support its attractiveness as an investment. However, technical indicators suggest caution, and challenges such as managing leverage and legal costs present risks. The positive earnings call and strategic corporate events further bolster the outlook.
To see Spark’s full report on GB:GSK stock, click here.
GSK announced that the US Advisory Committee on Immunization Practices has recommended the use of its RSV vaccine, Arexvy, for adults aged 50-59 who are at increased risk for severe RSV disease. This recommendation, which follows a successful phase III trial, could benefit over 13 million adults in the US and marks an expansion from previous recommendations for older age groups. The approval of this recommendation could significantly impact GSK’s operations by broadening the market for its RSV vaccine and offering protection to a larger segment of the population vulnerable to severe RSV outcomes.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score reflects a stable financial performance with notable strengths in specialty medicines growth and shareholder return strategies. The company’s fair valuation and strong dividend yield support its attractiveness as an investment. However, technical indicators suggest caution, and challenges such as managing leverage and legal costs present risks. The positive earnings call and strategic corporate events further bolster the outlook.
To see Spark’s full report on GB:GSK stock, click here.
GSK announced that its 5-in-1 meningococcal vaccine, Penmenvy, received a positive recommendation from the US Advisory Committee on Immunization Practices for use in individuals over 10 years old. This recommendation, if adopted, could simplify the vaccination process by reducing the number of injections required, potentially improving immunization rates among US adolescents and young adults. The vaccine, which combines components of GSK’s existing vaccines Bexsero and Menveo, is set to be available in the US by summer 2025. This development positions GSK to strengthen its market presence in the US, particularly in the MenB vaccine segment, where it already holds a significant share.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score reflects a stable financial performance with notable strengths in specialty medicines growth and shareholder return strategies. The company’s fair valuation and strong dividend yield support its attractiveness as an investment. However, technical indicators suggest caution, and challenges such as managing leverage and legal costs present risks. The positive earnings call and strategic corporate events further bolster the outlook.
To see Spark’s full report on GB:GSK stock, click here.
GSK has announced the purchase of 676,221 of its own ordinary shares as part of its ongoing buyback program. This transaction, conducted through Citigroup Global Markets Limited, reflects the company’s strategy to manage its capital structure and return value to shareholders. The shares will be held as treasury shares, and the total number of voting rights remains unchanged, providing stakeholders with a stable basis for their investment calculations.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score reflects a stable financial performance with notable strengths in specialty medicines growth and shareholder return strategies. The company’s fair valuation and strong dividend yield support its attractiveness as an investment. However, technical indicators suggest caution, and challenges such as managing leverage and legal costs present risks. The positive earnings call and strategic corporate events further bolster the outlook.
To see Spark’s full report on GB:GSK stock, click here.
GSK PLC announced the purchase of 914,000 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. The shares will be held as treasury shares, contributing to the company’s strategy to manage its capital structure effectively. This move is part of a non-discretionary agreement with the broker, reflecting GSK’s commitment to optimizing shareholder value and maintaining a robust financial position.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score reflects a stable financial performance with notable strengths in specialty medicines growth and shareholder return strategies. The company’s fair valuation and strong dividend yield support its attractiveness as an investment. However, technical indicators suggest caution, and challenges such as managing leverage and legal costs present risks. The positive earnings call and strategic corporate events further bolster the outlook.
To see Spark’s full report on GB:GSK stock, click here.
GSK plc announced the acquisition of ordinary shares by two key personnel, David Redfern, President of Corporate Development, and Victoria Whyte, Company Secretary. The shares were acquired following the reinvestment of dividends paid on April 10, 2025, and the transactions were conducted on the London Stock Exchange. This move reflects the company’s ongoing commitment to shareholder value and may positively impact investor confidence.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score reflects a stable financial performance with notable strengths in specialty medicines growth and shareholder return strategies. The company’s fair valuation and strong dividend yield support its attractiveness as an investment. However, technical indicators suggest caution, and challenges such as managing leverage and legal costs present risks. The positive earnings call and strategic corporate events further bolster the outlook.
To see Spark’s full report on GB:GSK stock, click here.
GSK has announced the purchase of 918,500 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a strategy to manage the company’s capital structure and return value to shareholders, with the purchased shares being held as treasury shares. The transaction reflects GSK’s commitment to enhancing shareholder value and maintaining a robust financial position.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s stock score reflects a stable financial performance with a focus on growth in specialty medicines and shareholder returns. While the technical analysis suggests caution, the company’s strategic initiatives, fair valuation, and strong earnings outlook support a favorable view. Challenges include managing leverage and legal costs, but the overall outlook remains positive.
To see Spark’s full report on GB:GSK stock, click here.
GSK plc announced the acquisition of American Depositary Shares (ADSs) by several of its independent non-executive directors, including Elizabeth McKee Anderson, Charles Bancroft, Dr. Hal Barron, Dr. Anne Beal, Dr. Harry Dietz, Dr. Jesse Goodman, and Dr. Jeannie Lee. These acquisitions were made following the reinvestment of dividends paid to shareholders on April 10, 2025. The transactions were conducted on the New York Stock Exchange at a price of $34.1210 per share. This move reflects the directors’ confidence in the company’s future performance and could potentially strengthen GSK’s market position by aligning the interests of its leadership with those of its shareholders.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s stock score reflects a stable financial performance with a focus on growth in specialty medicines and shareholder returns. While the technical analysis suggests caution, the company’s strategic initiatives, fair valuation, and strong earnings outlook support a favorable view. Challenges include managing leverage and legal costs, but the overall outlook remains positive.
To see Spark’s full report on GB:GSK stock, click here.
GSK plc announced the purchase of 1,286,688 of its own ordinary shares as part of its ongoing buyback program. The shares, bought at prices ranging from 1,268.00p to 1,299.50p, will be held in treasury. This move is part of a non-discretionary agreement with Citigroup Global Markets Limited, initiated in February 2025, and highlights GSK’s strategy to manage its capital structure and return value to shareholders.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s stock score reflects its stable financial performance, positive earnings outlook, and strategic corporate actions such as share buybacks and product approvals. While the technical analysis suggests caution, the company’s strong dividend yield and growth in specialty medicines support a favorable view, offsetting concerns about leverage and legal costs.
To see Spark’s full report on GB:GSK stock, click here.
GSK announced the acquisition of ordinary shares by several of its top executives under the company’s Share Reward Plan. This move, involving key figures such as the CEO and CFO, signifies a strategic alignment of management interests with shareholder value, potentially strengthening stakeholder confidence and enhancing the company’s market positioning.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score reflects its stable financial performance, fair valuation, and positive earnings call outlook, supported by strategic corporate events. Key strengths include growth in specialty medicines and a strong dividend yield. Risks include leverage management and legal costs.
To see Spark’s full report on GB:GSK stock, click here.
GSK has announced the purchase of 864,000 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired through Citigroup Global Markets Limited, will be held as treasury shares. This move is part of a non-discretionary agreement and contributes to the company’s strategy to manage its capital structure, potentially impacting shareholder value and market perception.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score reflects its stable financial performance, fair valuation, and positive earnings call outlook, supported by strategic corporate events. Key strengths include growth in specialty medicines and a strong dividend yield. Risks include leverage management and legal costs.
To see Spark’s full report on GB:GSK stock, click here.
GlaxoSmithKline (GSK) has announced a significant transaction involving the repurchase of 1,519,276 of its own ordinary shares, which will be held as treasury shares. This move is part of GSK’s ongoing buyback program, executed through Citigroup Global Markets Limited. The buyback is aimed at enhancing shareholder value and optimizing the company’s capital structure. Following this transaction, GSK holds a total of 194,312,216 ordinary shares in treasury, with the total number of voting rights standing at 4,120,914,866.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline shows stable financials with strong cash flow and moderate income growth. The technical analysis suggests some caution due to trading below key moving averages. Valuation is fair with a good dividend yield. Strong earnings call guidance and strategic corporate events, such as share buybacks and new product approvals, bolster the outlook despite legal and vaccine segment challenges.
To see Spark’s full report on GB:GSK stock, click here.
GSK has announced the purchase of 1,035,000 of its own ordinary shares, as part of its ongoing buyback program, through Citigroup Global Markets Limited. The shares, bought at an average price of 1,345.28 pence, will be held as treasury shares. This transaction, part of a non-discretionary agreement, reflects GSK’s strategy to optimize its capital structure and potentially enhance shareholder value. The company now holds 192,792,940 shares in treasury, with 4,122,434,142 shares in issue, impacting the total voting rights available to shareholders.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.
GlaxoSmithKline demonstrates a stable financial position with moderate income growth and strong cash flow management. The earnings call highlights robust sales in Specialty medicines, though legal costs and a slightly leveraged balance sheet present risks. The stock shows fair valuation with a strong dividend yield, supported by positive future guidance.
To see Spark’s full report on GB:GSK stock, click here.
GSK has announced the purchase of 1,454,000 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a non-discretionary agreement initiated in February 2025, and the shares will be held as treasury shares. The buyback program is a strategic effort to manage the company’s capital structure and return value to shareholders, reflecting GSK’s confidence in its financial health and future prospects.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score reflects its stable financial performance, positive earnings call, and fair valuation. Key strengths include sales growth in specialty medicines and a strong dividend yield. Challenges in managing leverage and legal costs are notable risks, but the company’s strategic initiatives and positive guidance support a favorable outlook.
To see Spark’s full report on GB:GSK stock, click here.
GSK has announced the repurchase of 808,000 of its ordinary shares as part of its ongoing buyback program. This transaction, facilitated by Citigroup Global Markets Limited, reflects GSK’s strategy to enhance shareholder value and optimize its capital structure. The shares, purchased at prices ranging from 1,413.00p to 1,468.50p, will be held as treasury shares, contributing to a total of 190,303,940 shares in treasury. This move underscores GSK’s commitment to returning value to its shareholders and maintaining a strong financial position.
GSK has announced the purchase of 739,200 of its own ordinary shares as part of its ongoing share buyback program. This move, executed through Citigroup Global Markets Limited, reflects GSK’s strategy to optimize its capital structure and enhance shareholder value. The shares will be held as treasury shares, contributing to the company’s financial flexibility and potentially impacting its market positioning by reducing the number of shares available in the market.
GSK has announced the purchase of 819,550 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategy to manage its capital structure and return value to shareholders. The shares will be held as treasury shares, contributing to the company’s financial flexibility and potentially impacting shareholder voting rights.
GSK has announced a recent transaction involving the repurchase of 630,000 of its ordinary shares, as part of its ongoing buyback program. This move, executed through Citigroup Global Markets Limited, aims to consolidate the company’s share capital and potentially enhance shareholder value by holding these shares in treasury. The buyback reflects GSK’s strategic financial management and may influence shareholder interest calculations under regulatory guidelines.
GSK plc has announced its total voting rights and capital as of March 31, 2025, in compliance with the Financial Conduct Authority’s rules. The company’s issued share capital consists of over 4.3 billion shares, with 187 million held in treasury, resulting in a total of approximately 4.1 billion voting rights. This information is crucial for shareholders to determine their notification requirements under regulatory guidelines.
GSK announced the purchase of 836,600 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This action is part of a non-discretionary agreement initiated in February 2025, and the shares will be held in treasury, impacting the company’s share structure and potentially influencing shareholder value.
GSK has announced the purchase of 834,200 of its own ordinary shares, which will be held as treasury shares. This transaction is part of the company’s ongoing buyback program, executed through Citigroup Global Markets Limited. The buyback is aimed at optimizing the company’s capital structure and enhancing shareholder value. Following this purchase, GSK holds a total of 186,470,590 ordinary shares in treasury, with 4,128,751,142 shares in issue. This move may influence shareholder voting rights and is a strategic step in GSK’s financial management.
GSK plc has announced the release of American Depositary Shares (ADSs) for several of its non-executive directors following the termination of the GSK Non-Executive Director Share Allocation Arrangements. The directors, including Charles Bancroft, Dr Anne Beal, Dr Hal Dietz, and Dr Jesse Goodman, have received their respective ADSs, with a portion withheld for tax purposes. These shares will be held by the directors until their retirement from the board, reflecting a strategic move in managing executive compensation and aligning with shareholder interests.
GSK plc has announced the purchase of 847,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategic financial management and may influence shareholder value by reducing the number of shares in circulation, potentially increasing earnings per share.
GlaxoSmithKline (GSK) has announced the purchase of 847,000 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired through Citigroup Global Markets Limited, will be held as treasury shares, contributing to a total of 184,789,390 shares in treasury. This move is part of a non-discretionary agreement initiated on 24 February 2025, and since then, GSK has repurchased a total of 15,719,087 shares. The buyback program is a strategic effort to manage the company’s capital structure and potentially enhance shareholder value.
GSK has announced the purchase of 835,000 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move, which involves holding the shares in treasury, is part of a non-discretionary agreement initiated in February 2025, and it reflects GSK’s strategy to manage its capital structure and enhance shareholder value.
GSK plc announced the purchase of 587,100 of its own ordinary shares as part of its ongoing share buyback program. The shares were acquired at prices ranging from 1,482.00p to 1,516.00p, with a volume-weighted average price of 1,490.87p. This transaction, executed through Citigroup Global Markets Limited, adds to the 14,037,087 shares already repurchased since February 2025, reflecting GSK’s strategy to enhance shareholder value and optimize its capital structure.
GSK announced that the US FDA has approved Blujepa (gepotidacin), a first-in-class oral antibiotic for treating uncomplicated urinary tract infections (uUTIs) in female adults and pediatric patients aged 12 and older. This approval marks a significant milestone as Blujepa is the first new class of oral antibiotics for uUTIs in nearly 30 years, addressing the growing issue of drug-resistant bacteria. The approval is based on positive results from phase III EAGLE-2 and EAGLE-3 trials, which demonstrated Blujepa’s efficacy and safety compared to the standard treatment, nitrofurantoin. The commercial launch in the US is planned for the second half of 2025, and the development has been partially funded by US federal agencies.
GSK announced that the European Medicines Agency has accepted its application to expand the use of Nucala (mepolizumab) for treating COPD with an eosinophilic phenotype. The application is backed by the successful phase III MATINEE trial, which demonstrated a significant reduction in moderate/severe exacerbations in COPD patients. If approved, Nucala could become the first monthly biologic treatment for COPD, addressing a major need for targeted therapies in a disease affecting over 40 million people in Europe.
GSK has announced the purchase of 570,000 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a non-discretionary agreement and reflects GSK’s strategic approach to managing its capital structure, potentially enhancing shareholder value and signaling confidence in the company’s financial health.
GSK plc announced transactions involving the purchase of shares by several of its board members, including Sir Jonathan Symonds, Wendy Becker, Elizabeth McKee Anderson, Charles Bancroft, Dr Hal Barron, Dr Anne Beal, Dr Hal Dietz, and Dr Jesse Goodman. These transactions, conducted on March 20, 2025, involved the acquisition of both Ordinary Shares on the London Stock Exchange and American Depositary Shares on the New York Stock Exchange. The purchases reflect confidence in the company’s future prospects and may influence investor perception positively.
GSK plc has announced the purchase of 565,320 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategic move to manage its capital structure and potentially enhance shareholder value by holding these shares in treasury.
GSK has announced the purchase of 556,200 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which took place on March 19, 2025, is part of a non-discretionary agreement and highlights GSK’s strategic efforts to manage its capital structure and enhance shareholder value. The shares will be held as treasury shares, and the total number of voting rights remains unchanged at 4,133,820,322, providing stakeholders with a clear understanding of their shareholding status.
GSK has announced the purchase of 552,000 of its own ordinary shares as part of its ongoing share buyback program, executed through Citigroup Global Markets Limited. This transaction is part of a broader strategy to manage capital structure and return value to shareholders, reflecting GSK’s commitment to maintaining a robust financial position and enhancing shareholder value.
GSK has announced the purchase of 745,425 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which took place on 17 March 2025, reflects GSK’s strategic initiative to manage its capital structure and enhance shareholder value by holding these shares in treasury, thereby potentially impacting the company’s stock market performance and investor relations.
GSK announced the purchase of 690,000 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which involved shares priced between 1,495.50p and 1,513.50p, aims to consolidate the company’s capital structure by holding the acquired shares as treasury shares, thereby potentially enhancing shareholder value.
GSK plc announced the acquisition of ordinary shares by several of its senior executives, including the CEO and CFO, under the company’s Share Reward Plan. Each executive acquired 16 ordinary shares at a price of £15.4540 per share, with transactions conducted on the London Stock Exchange. This move reflects the company’s commitment to aligning the interests of its leadership with those of its shareholders, potentially strengthening stakeholder confidence in GSK’s strategic direction.
GSK announced the purchase of 755,000 of its own shares as part of an ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which took place on 13 March 2025, is part of a strategy to manage the company’s capital structure and return value to shareholders. The shares will be held as treasury shares, and the company now holds a total of 178,841,345 shares in treasury. This move is expected to impact the company’s financial metrics and shareholder value positively.
GSK plc announced the purchase of 755,000 of its own ordinary shares as part of its ongoing buyback program, executed through its broker, Citigroup Global Markets Limited. This transaction is part of a non-discretionary agreement and contributes to the company’s strategy of managing its capital structure efficiently, potentially enhancing shareholder value.
GSK plc announced the purchase of 724,000 of its own ordinary shares, as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. The shares, bought at a volume-weighted average price of 1,525.77 pence, will be held as treasury shares, contributing to a total of 177,331,345 shares in treasury. This move is part of a strategic effort to manage the company’s capital structure and enhance shareholder value.
GSK has announced the purchase of 508,000 of its own ordinary shares, which will be held as treasury shares, as part of its ongoing buyback program. This move is part of a non-discretionary agreement with Citigroup Global Markets Limited, aiming to manage the company’s capital structure and return value to shareholders.
GlaxoSmithKline (GSK) announced the purchase of 500,700 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which involved shares priced between 1,497.00p and 1,535.00p, contributes to GSK’s strategy to manage its capital structure and return value to shareholders, with a total of 7,029,042 shares purchased since the program’s initiation.
GSK announced the purchase of 782,440 of its own ordinary shares as part of its ongoing buyback program, with the shares to be held as treasury shares. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategy to manage its capital structure and potentially enhance shareholder value. The buyback program, initiated on February 24, 2025, has seen a total of 5,821,342 shares repurchased, indicating a significant commitment to this financial strategy.
GSK plc has announced the purchase of 547,800 of its own ordinary shares, as part of its ongoing buyback program, through its broker Citigroup Global Markets Limited. This transaction, executed on March 4, 2025, is part of a non-discretionary agreement and reflects the company’s strategy to manage its capital structure, potentially impacting shareholder value and market perception.
GSK has announced the repurchase of 547,800 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a strategic effort to manage its capital structure and enhance shareholder value, with the shares being held in treasury. The company now holds a total of 174,109,205 shares in treasury, with 4,141,068,225 shares in issue, excluding treasury shares, impacting the total number of voting rights available to shareholders.
GSK announced the purchase of 537,500 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. The shares, bought at prices ranging from 1,469.00p to 1,495.00p, will be held as treasury shares. This move is part of a strategic effort to manage capital and enhance shareholder value, reflecting GSK’s commitment to maintaining a robust financial position and potentially impacting its market valuation positively.
GSK has filed its 2024 Annual Report on Form 20-F with the SEC, which includes audited financial statements for the year ending December 31, 2024. The report is accessible online, and shareholders can request a hard copy. This filing is a routine disclosure that provides transparency and accountability to shareholders and stakeholders, reinforcing GSK’s commitment to regulatory compliance and financial transparency.
GSK plc has announced its total voting rights and capital structure as of February 28, 2025. The company reported an issued share capital of 4,315,177,430 shares, with 173,023,905 shares held in treasury, resulting in a total of 4,142,153,525 voting rights. This information is crucial for shareholders to determine their interests under the Financial Conduct Authority’s rules, impacting their decision-making and compliance obligations.
GSK announced that the US FDA has accepted the Biologics License Application for depemokimab, a monoclonal antibody targeting IL-5, for review as a treatment for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). If approved, depemokimab will be the first ultra-long-acting biologic with a six-month dosing regimen, potentially reducing the burden on patients and healthcare systems. The SWIFT and ANCHOR trials demonstrated depemokimab’s efficacy in reducing asthma exacerbations and nasal polyp size, highlighting its potential to improve patient care and adherence to treatment.
GSK plc has announced the repurchase of 542,550 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, completed on February 28, 2025, is part of a non-discretionary agreement and contributes to the company’s strategy of managing its capital structure. The shares will be held in treasury, impacting the total number of voting rights and potentially affecting shareholder interests in line with the Financial Conduct Authority’s rules.
GSK announced positive results from its ANCHOR-1 and ANCHOR-2 phase III trials for depemokimab, a monoclonal antibody targeting IL-5, in treating chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated significant improvements in nasal polyp size and obstruction with a twice-yearly dosing regimen. These findings, presented at the AAAAI/WAO Joint Congress and published in The Lancet, highlight depemokimab’s potential as an alternative to current treatments, which often require repeat surgeries and long-term corticosteroid use. The results could impact regulatory filings and support the drug’s use in other IL-5 mediated diseases.
GlaxoSmithKline (GSK) has announced a significant transaction involving the repurchase of its own shares. The company, through its broker Citigroup Global Markets Limited, has acquired 800,000 ordinary shares as part of its existing buyback program. This move is part of a broader strategy to manage its capital structure and potentially enhance shareholder value. The shares will be held in treasury, and the total number of voting rights in the company remains unchanged at 4,142,685,716. This transaction reflects GSK’s ongoing commitment to optimizing its financial operations and maintaining a robust market presence.
GSK has published its Annual Report for the year ending December 31, 2024, which is now available on the company’s website and has been submitted to the UK’s Financial Conduct Authority’s National Storage Mechanism for inspection. The report complies with the FCA’s disclosure requirements, and shareholders who opted for paper communications will receive a hard copy along with the Notice of Annual General Meeting 2025 around March 24, 2025.
GlaxoSmithKline (GSK) has announced a share buyback transaction, purchasing 800,000 of its ordinary shares through Citigroup Global Markets Limited. This purchase is part of GSK’s ongoing buyback program, which aims to manage the company’s capital structure and return value to shareholders. The shares will be held as treasury shares, and the total number of voting rights in the company remains at 4,143,485,716. This move reflects GSK’s strategic focus on optimizing shareholder value and maintaining financial flexibility.
GSK plc announced several transactions involving its senior executives, including the acquisition and sale of shares. Dr. Hal Barron, a Non-Executive Director, acquired American Depositary Shares (ADSs) through reinvestment of dividends, while James Ford, SVP and Group General Counsel, also acquired ADSs and sold ordinary shares. CEO Emma Walmsley gifted ordinary shares to a family member. These transactions reflect the ongoing financial activities and investment strategies of GSK’s leadership, potentially impacting shareholder perceptions and market confidence.
GSK has announced the repurchase of 809,900 of its ordinary shares as part of its ongoing buyback program, with the shares to be held as treasury shares. This move, executed through Citigroup Global Markets Limited, is part of a non-discretionary agreement and reflects GSK’s strategy to manage its capital structure, potentially impacting shareholder value and market perception.
GSK has announced the purchase of 1,001,152 of its own ordinary shares as part of its ongoing buyback program. These shares, bought at a volume-weighted average price of 1,450.90 GBp, will be held as treasury shares, reflecting the company’s strategy to enhance shareholder value and optimize its capital structure.
GSK has finalized its acquisition of IDRx, Inc., a clinical-stage biopharmaceutical company based in Boston, for up to $1.15 billion. This acquisition includes IDRX-42, a promising tyrosine kinase inhibitor designed to address gastrointestinal stromal tumours (GIST) with both primary and secondary KIT mutations. The strategic acquisition is expected to enhance GSK’s oncology pipeline, particularly in the treatment of GIST where current therapies fall short, thereby potentially improving outcomes for patients with this condition.
GSK plc announced the vesting of Deferred Bonus Awards under its 2017 Deferred Annual Bonus Plan for its managers and directors. The awards, granted in 2022, have been exercised as nil-cost options or restricted awards over Ordinary Shares and American Depositary Shares (ADSs), with sales made primarily to cover tax liabilities. This move highlights GSK’s commitment to its remuneration policy and could impact shareholder value by aligning managerial interests with company performance.
GSK announced the vesting details of awards under the 2017 Performance Share Plan for certain managerial personnel. The company achieved significant performance measures over a three-year period ending December 2024, with strong results in shareholder return, sales, profit, and environmental goals, reflecting positively on its strategic objectives. The vested shares for executive directors are now subject to an additional two-year period. This announcement underscores GSK’s operational achievements and commitment to long-term growth, impacting stakeholders favorably with its robust performance metrics.
GSK plc announced a transaction involving its Chief Scientific Officer, Tony Wood. As part of the GlaxoSmithKline Deferred Investment Award Programme, Tony Wood received a cash payment of £247,942.28, equivalent to 17,182.417 notional Ordinary Shares, following the vesting of an award from 2021. This transaction highlights GSK’s compensation strategies and its commitment to rewarding key personnel, potentially impacting stakeholder perceptions of the company’s leadership incentives.
GSK plc announced the granting of conditional share awards under its 2017 Performance Share Plan to senior executives, including executive directors and other key management personnel. These awards, contingent on meeting performance targets over a three-year period from 2025 to 2027, aim to align managerial incentives with company performance goals. The plan’s structure, including additional holding periods for executive directors, underscores GSK’s commitment to long-term growth and shareholder value, with potential implications for executive retention and motivation.
GSK has announced the appointment of Dr. Gavin Screaton as a Non-Executive Director, effective May 1, 2025. Dr. Screaton, an expert in immunology and infectious diseases, will replace Dr. Jesse Goodman, who is retiring after nine years of service. Dr. Screaton’s extensive experience in public health and his current role at the University of Oxford will enhance GSK’s expertise in its core scientific areas. This strategic move is expected to strengthen GSK’s board as it continues to focus on its biopharmaceutical endeavors, potentially impacting its positioning in the industry and its stakeholders.
GSK announced the granting of awards under the 2017 Deferred Annual Bonus Plan to several key executives, including the CEO and CFO, requiring them to defer portions of their bonuses into Ordinary Shares or American Depositary Shares for three years. This move, aligned with shareholder-approved remuneration policies, aims to reinforce commitment to the company’s long-term performance and align the interests of its executives with those of the stakeholders.
GSK announced that the China National Medical Products Administration has accepted the review of its new drug application for Nucala (mepolizumab) as an add-on treatment for COPD with an eosinophilic phenotype. The submission is supported by data from the MATINEE trial, which demonstrated significant reductions in exacerbations among a broad population of COPD patients. If approved, Nucala could become the first approved biologic with monthly dosing for COPD, potentially offering a new treatment option for a significant portion of the 100 million people with COPD in China.
GSK announced that its 5-in-1 meningococcal vaccine, Penmenvy, has received approval from the US FDA for use in individuals aged 10 to 25 years. This vaccine, which protects against the five serogroups of Neisseria meningitidis, aims to improve vaccination rates among US adolescents and young adults, who are at higher risk for invasive meningococcal disease (IMD). The approval positions GSK to enhance its leadership in the US meningococcal vaccine market, with implications for increasing protection against serogroup B, the leading cause of IMD among young people.
GSK plc, a leading pharmaceutical company, announced a series of transactions involving the acquisition of ordinary shares by several of its top executives under the company’s Share Reward Plan. The transactions were conducted on February 11, 2025, at the London Stock Exchange. This move reflects the company’s ongoing commitment to align executive interests with those of shareholders, potentially impacting stakeholder confidence positively.
GSK announced several transactions involving the vesting and sale of ordinary shares under its Performance Share Plan and Deferred Investment Award Programme. The transactions involve key executives, including the CEO, and are part of the company’s ongoing employee compensation and incentive strategies. These moves could impact the company’s financials and stakeholder interests by aligning management incentives with long-term company performance.
GSK reported a robust performance for 2024 with a total sales increase of 7% at constant exchange rates, driven by significant growth in specialty medicines despite a decline in vaccine sales. The company faced a notable decline in total operating profit and EPS primarily due to a substantial charge related to Zantac litigation. However, GSK’s specialty medicines portfolio showed strong momentum, bolstered by advancements in its pipeline and strategic acquisitions. Looking ahead, GSK anticipates growth in turnover, core operating profit, and EPS for 2025, supported by its R&D investments and a planned share buyback program. The company has also raised its 2031 sales outlook, underscoring its strategic focus on long-term growth and shareholder returns.